Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis.
作者信息
Buononato Dario, Licata Gaetano, Gambardella Alessio, De Rosa Alina, Calabrese Giulia, Argenziano Giuseppe
机构信息
Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
出版信息
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022049. doi: 10.5826/dpc.1202a49. eCollection 2022 May.
Abstract
摘要
相似文献
1
Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis.替拉珠单抗：两名银屑病关节炎患者的成功治疗反应
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022049. doi: 10.5826/dpc.1202a49. eCollection 2022 May.
2
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.替度鲁单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照、多剂量、52 周的 IIb 期研究结果。
Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.
3
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.在一项2b期和两项3期试验中，根据患者人口统计学和疾病特征评估替拉珠单抗治疗中重度慢性斑块状银屑病的疗效。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1500-1509. doi: 10.1111/jdv.16187. Epub 2020 Feb 9.
4
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.古塞奇尤单抗：首个用于治疗成人活动性银屑病关节炎的选择性 IL-23 抑制剂。
Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7.
5
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.替拉珠单抗的潜在效用：一种用于治疗银屑病的白细胞介素-23抑制剂。
Expert Opin Investig Drugs. 2017 Feb;26(2):243-249. doi: 10.1080/13543784.2017.1274734. Epub 2017 Jan 1.
6
Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment.使用替拉珠单抗治疗银屑病甲病和银屑病关节炎的临床改善情况。
Dermatol Ther. 2020 Mar;33(2):e13216. doi: 10.1111/dth.13216. Epub 2020 Jan 8.
7
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.替拉珠单抗治疗银屑病：最新证据及在治疗中的地位
Ther Adv Chronic Dis. 2019 Aug 12;10:2040622319865658. doi: 10.1177/2040622319865658. eCollection 2019.
8
Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.替拉珠单抗：用于治疗中度至重度银屑病的抗白细胞介素-23p19单克隆抗体。
Drugs Today (Barc). 2018 Jul;54(7):433-444. doi: 10.1358/dot.2018.54.7.2866117.
9
Tildrakizumab for the treatment of psoriasis.替西单抗治疗银屑病。
Expert Rev Clin Immunol. 2019 Jan;15(1):5-12. doi: 10.1080/1744666X.2019.1544493. Epub 2018 Nov 14.
10
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.治疗中重度银屑病患者的高亲和力、选择性抗白细胞介素 23p19 单克隆抗体替度鲁单抗（MK-3222）对细胞色素 P450 代谢的影响。
Br J Clin Pharmacol. 2018 Oct;84(10):2292-2302. doi: 10.1111/bcp.13670. Epub 2018 Jul 31.
引用本文的文献
1
Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights.特应性皮炎：对这种有趣疾病的全面更新综述及未来展望。
Inflammopharmacology. 2025 Mar;33(3):1161-1187. doi: 10.1007/s10787-025-01642-z. Epub 2025 Feb 7.
本文引用的文献
1
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.古塞奇尤单抗：首个用于治疗成人活动性银屑病关节炎的选择性 IL-23 抑制剂。
Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7.
2
Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.银屑病关节炎中白细胞介素-23 信号通路的病理生理学和抑制：分子见解。
Clin Immunol. 2019 Sep;206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6.
Zotero 插件